Tin tức & Cập nhật
Xem bài viết Tiêu hóa
Xem
Chỉ hiển thị Multimedia

Seladelpar improves liver outcomes in cirrhosis patients with PBC, portal hypertension
21 Jun 2026
bởiStephen Padilla
Treatment with seladelpar for 4 years yields consistent biochemical efficacy, with no new safety concerns, among patients with cirrhosis and primary biliary cholangitis (PBC), as shown by interim results from the open-label ASSURE study.








